AIHTA - Publications - Search - Horizon Scanning in Oncology 35th Prioritisation – 2nd quarter 2018

Grössmann, N. and Rothschedl, E. and Wolf, S. (2018): Horizon Scanning in Oncology 35th Prioritisation – 2nd quarter 2018. HSO: 35th Prioritisation.

[thumbnail of HSO_35th_Prioritisation.pdf]
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader

For the 35th prioritisation (March 2018), eight drugs were filtered out of 404 identified and were sent to prioritisation. Of these, six drugs were ranked as 'highly relevant' by the expert panel, one as 'relevant' and one as 'not relevant'. For 'highly relevant' drugs, further information including, for example, abstracts of phase III studies and licensing status is contained in this document.

Item Type:DSD: Horizon Scanning in Oncology
Subjects:WB Practice of medicine > WB 300-962 Therapeutics
QZ Pathology > QZ 200-380 Neoplasms.Cysts
QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
Series Name:HSO: 35th Prioritisation
Deposited on:06 Apr 2018 10:31
Last Modified:15 Jul 2020 17:57

Repository Staff Only: item control page